These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27446438)

  • 1. Plasma long non-coding RNA MALAT1 is associated with distant metastasis in patients with epithelial ovarian cancer.
    Chen Q; Su Y; He X; Zhao W; Wu C; Zhang W; Si X; Dong B; Zhao L; Gao Y; Yang X; Chen J; Lu J; Qiao X; Zhang Y
    Oncol Lett; 2016 Aug; 12(2):1361-1366. PubMed ID: 27446438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MALAT1 affects ovarian cancer cell behavior and patient survival.
    Lin Q; Guan W; Ren W; Zhang L; Zhang J; Xu G
    Oncol Rep; 2018 Jun; 39(6):2644-2652. PubMed ID: 29693187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility Of Plasma circBNC2 As A Diagnostic Biomarker In Epithelial Ovarian Cancer.
    Hu Y; Zhu Y; Zhang W; Lang J; Ning L
    Onco Targets Ther; 2019; 12():9715-9723. PubMed ID: 32009804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA MALAT1 Promotes Survival of Epithelial Ovarian Cancer Cells by Downregulating miR-145-5p.
    Wang K; Zhao Y; Wang YM
    Cancer Manag Res; 2020; 12():11359-11369. PubMed ID: 33192095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating ciRS-7 as a potential non-invasive biomarker for epithelial ovarian cancer: An investigative study.
    Beilerli A; Begliarzade S; Sufianov A; Ilyasova T; Liang Y; Beylerli O
    Noncoding RNA Res; 2022 Sep; 7(3):197-204. PubMed ID: 35991513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway.
    Jin Y; Feng SJ; Qiu S; Shao N; Zheng JH
    Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3176-3184. PubMed ID: 28770968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis.
    Xia H; Chen Q; Chen Y; Ge X; Leng W; Tang Q; Ren M; Chen L; Yuan D; Zhang Y; Liu M; Gong Q; Bi F
    Oncotarget; 2016 Aug; 7(35):56209-56218. PubMed ID: 27486823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non‑coding RNA MALAT1 serves as an independent predictive biomarker for the diagnosis, severity and prognosis of patients with sepsis.
    Chen J; He Y; Zhou L; Deng Y; Si L
    Mol Med Rep; 2020 Mar; 21(3):1365-1373. PubMed ID: 31922243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients.
    Huo J; Hu J; Liu G; Cui Y; Ju Y
    Arch Gynecol Obstet; 2017 Feb; 295(2):459-465. PubMed ID: 27975129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
    Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
    Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of the clinicopathological significance of the lncRNA MALAT1 in human gastric cancer.
    Bai S; Guo J; Zhang H
    Front Oncol; 2023; 13():1257120. PubMed ID: 38239645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of metastasis-associated lung adenocarcinoma transcript 1 long non-coding RNA
    Lin L; Li H; Zhu Y; He S; Ge H
    Oncol Lett; 2018 Jun; 15(6):9443-9449. PubMed ID: 29805668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer.
    Chen Q; Ge X; Zhang Y; Xia H; Yuan D; Tang Q; Chen L; Pang X; Leng W; Bi F
    Oncol Rep; 2014 Apr; 31(4):1863-70. PubMed ID: 24481716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer.
    Pang EJ; Yang R; Fu XB; Liu YF
    Tumour Biol; 2015 Apr; 36(4):2403-7. PubMed ID: 25481511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA MALAT1 can serve as a valuable biomarker for prognosis and lymph node metastasis in various cancers: a meta-analysis.
    Shuai P; Zhou Y; Gong B; Jiang Z; Yang C; Yang H; Zhang D; Zhu S
    Springerplus; 2016; 5(1):1721. PubMed ID: 27777857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The down-regulation of long non-coding RNA LINC01088 is associated with the poor prognosis of epithelial ovarian cancer patients.
    Ai H; Xie W; Xiu AH; Li N; Zhang ST; Zhang YL; Xue XO
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5836-5841. PubMed ID: 30280763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression.
    Zhang Y; Chen Z; Li MJ; Guo HY; Jing NC
    Biomed Pharmacother; 2017 Jan; 85():264-271. PubMed ID: 27887846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer.
    Li C; Cui Y; Liu LF; Ren WB; Li QQ; Zhou X; Li YL; Li Y; Bai XY; Zu XB
    Clin Genitourin Cancer; 2017 Oct; 15(5):570-576. PubMed ID: 28648755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Long Non-coding RNA MALAT1 Expression in Tissue and Serum of Breast Cancer.
    Miao Y; Fan R; Chen L; Qian H
    Ann Clin Lab Sci; 2016 Jul; 46(4):418-24. PubMed ID: 27466303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.